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Dear editor; Currently, control and prevention of respiratory
illnesses is considered a health priority in most developed
countries and managing the risk factors is necessary for im-
proving the population’s health (1, 2). Chronic obstructive
pulmonary disease (COPD) is the 5th cause of death around
the world and estimations have indicated that due to an in-
crease in environmental pollution, this disease will become
the 3rd cause of death in the future (1, 3).
In previous studies, pulmonary infection with mycoplasma
pneumoniae has been introduced as one of the causes for
COPD exacerbation. Mycoplasma pneumoniae affects the
upper and lower respiratory tract and its clinical manifesta-
tion is trachea-bronchitis accompanied by restlessness and
dry coughs (4, 5). The pathogenesis spectrum of this bac-
terium ranges from mild pharyngitis and trachea-bronchitis
to acute pneumonia. Epidemiologic studies have shown that
this bacterium is responsible for more than 20% of commu-
nity acquired pneumonias (6).
In a cross-sectional study by the authors of the present let-
ter, 66 patients over the age of 18 years who had presented
to the emergency department of Imam Reza Hospital, Mash-
had, Iran, with diagnosis of COPD exacerbation were eval-
uated. Sputum sample of the patients was obtained and
sent to the laboratory for performing polymerase chain re-
action (PCR). Mean age of the patients participating in this
study was 67.28 ± 13.68 years (60.6% male). The result of
PCR was positive in 6 patients out of the total of 66 patients
(9.1%). The results of the present study showed that there was
no correlation between age (p=0.18), sex (p=0.25), duration
of being affected with COPD (p=0.20), consumption of an-
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tibiotics (p=0.35), smoking (p=0.62), opioid abuse (p=0.44),
corticosteroid use (p=0.57), underlying illness (p=0.94) and
health care–associated pneumonia (HCAP) (p=0.46) with
mycoplasma infection. However, prevalence of leukocytosis
(p=0.01) and myalgia (p=0.02) was significantly higher in the
mycoplasma group.
Numerous studies have confirmed the presence of my-
coplasma pneumoniae in exacerbation of COPD using sero-
logic diagnosis. For instance, in a study by Lieberman et al.
(7) prevalence of mycoplasma pneumoniae in patients with
COPD exacerbation was reported as 14.2% and in Meloni et
al. (8) study the prevalence of this infection was expressed to
be 6.7%. These rates were reported between 5% and 14% in
other studies (9-11).
Thus, it seems that prevalence of mycoplasma is high in
COPD exacerbation, but there is still no answer to the ques-
tion if this infection results in exacerbation of COPD or not
and there is controversy between the studies in this regard
(4, 7, 12). Therefore, it is suggested to design case-control or
cohort studies to find the answer to this question.
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